nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—Vandetanib—thyroid cancer	0.702	0.899	CbGbCtD
Gliclazide—ALB—Vandetanib—thyroid cancer	0.0459	0.0588	CbGbCtD
Gliclazide—CYP2C19—Sorafenib—thyroid cancer	0.0179	0.023	CbGbCtD
Gliclazide—CYP2C9—Sorafenib—thyroid cancer	0.0149	0.0191	CbGbCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00196	0.0306	CbGpPWpGaD
Gliclazide—VEGFA—Cellular response to hypoxia—EPO—thyroid cancer	0.00158	0.0246	CbGpPWpGaD
Gliclazide—Glipizide—PPARG—thyroid cancer	0.00152	1	CrCbGaD
Gliclazide—VEGFA—HIF-2-alpha transcription factor network—EPO—thyroid cancer	0.00123	0.0192	CbGpPWpGaD
Gliclazide—VEGFA—Beta1 integrin cell surface interactions—LAMA2—thyroid cancer	0.00112	0.0174	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—CDK1—thyroid cancer	0.00106	0.0166	CbGpPWpGaD
Gliclazide—VEGFA—Glypican 1 network—NRG1—thyroid cancer	0.00106	0.0165	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—HIF1A—thyroid cancer	0.00097	0.0151	CbGpPWpGaD
Gliclazide—VEGFA—Cellular response to hypoxia—HIF1A—thyroid cancer	0.000939	0.0146	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—EPO—thyroid cancer	0.000936	0.0146	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.000924	0.0144	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—thyroid cancer	0.000897	0.014	CbGpPWpGaD
Gliclazide—ABCC8—Regulation of insulin secretion—PRKAR1A—thyroid cancer	0.00088	0.0137	CbGpPWpGaD
Gliclazide—KCNJ11—Regulation of insulin secretion—PRKAR1A—thyroid cancer	0.000853	0.0133	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—HIF1A—thyroid cancer	0.000834	0.013	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—PTCH1—thyroid cancer	0.000806	0.0126	CbGpPWpGaD
Gliclazide—VEGFA—S1P1 pathway—PTGS2—thyroid cancer	0.000782	0.0122	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—RET—thyroid cancer	0.00074	0.0115	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000725	0.0113	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—NKX2-1—thyroid cancer	0.0007	0.0109	CbGpPWpGaD
Gliclazide—ABCC8—Integration of energy metabolism—PRKAR1A—thyroid cancer	0.000692	0.0108	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.000688	0.0107	CbGpPWpGaD
Gliclazide—KCNJ11—Integration of energy metabolism—PRKAR1A—thyroid cancer	0.000671	0.0105	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—BRAF—thyroid cancer	0.000654	0.0102	CbGpPWpGaD
Gliclazide—ALB—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000638	0.00993	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000637	0.00992	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000581	0.00905	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—LAMA2—thyroid cancer	0.000479	0.00746	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—CCND1—thyroid cancer	0.000478	0.00744	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TPR—thyroid cancer	0.000477	0.00743	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.000457	0.00712	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000451	0.00703	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HIF1A—thyroid cancer	0.000437	0.00681	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000432	0.00673	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—CDK1—thyroid cancer	0.000426	0.00663	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—CDK1—thyroid cancer	0.000402	0.00626	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000385	0.00601	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—NRAS—thyroid cancer	0.000382	0.00595	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—SST—thyroid cancer	0.000361	0.00563	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—thyroid cancer	0.000349	0.00544	CbGpPWpGaD
Gliclazide—ALB—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.000333	0.00519	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—KRAS—thyroid cancer	0.000329	0.00512	CbGpPWpGaD
Gliclazide—CYP2C19—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000329	0.00512	CbGpPWpGaD
Gliclazide—VEGFA—Angiogenesis—AKT1—thyroid cancer	0.000326	0.00508	CbGpPWpGaD
Gliclazide—VEGFA—S1P3 pathway—AKT1—thyroid cancer	0.000316	0.00492	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—TP53—thyroid cancer	0.000315	0.0049	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—HRAS—thyroid cancer	0.000301	0.00469	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.0003	0.00467	CbGpPWpGaD
Gliclazide—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.0003	0.00467	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CHST14—thyroid cancer	0.00029	0.00452	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR1 specific signals—AKT1—thyroid cancer	0.00028	0.00437	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—HRAS—thyroid cancer	0.000279	0.00435	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.000264	0.00412	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000258	0.00402	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—NRAS—thyroid cancer	0.000249	0.00388	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000248	0.00387	CbGpPWpGaD
Gliclazide—Dyspepsia—Sorafenib—thyroid cancer	0.00024	0.00157	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—EPO—thyroid cancer	0.000239	0.00373	CbGpPWpGaD
Gliclazide—Coma—Doxorubicin—thyroid cancer	0.000239	0.00156	CcSEcCtD
Gliclazide—Oesophagitis—Doxorubicin—thyroid cancer	0.000239	0.00156	CcSEcCtD
Gliclazide—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000238	0.00155	CcSEcCtD
Gliclazide—Thrombophlebitis—Epirubicin—thyroid cancer	0.000237	0.00154	CcSEcCtD
Gliclazide—Neoplasm—Doxorubicin—thyroid cancer	0.000237	0.00154	CcSEcCtD
Gliclazide—Bladder pain—Doxorubicin—thyroid cancer	0.000237	0.00154	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000236	0.00154	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000236	0.00154	CcSEcCtD
Gliclazide—Fatigue—Sorafenib—thyroid cancer	0.000236	0.00153	CcSEcCtD
Gliclazide—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000235	0.00153	CcSEcCtD
Gliclazide—Photosensitivity—Epirubicin—thyroid cancer	0.000234	0.00152	CcSEcCtD
Gliclazide—Constipation—Sorafenib—thyroid cancer	0.000234	0.00152	CcSEcCtD
Gliclazide—Pain—Sorafenib—thyroid cancer	0.000234	0.00152	CcSEcCtD
Gliclazide—Eczema—Epirubicin—thyroid cancer	0.000229	0.00149	CcSEcCtD
Gliclazide—Hepatic failure—Epirubicin—thyroid cancer	0.000229	0.00149	CcSEcCtD
Gliclazide—Abnormal vision—Doxorubicin—thyroid cancer	0.000228	0.00149	CcSEcCtD
Gliclazide—Mental disability—Doxorubicin—thyroid cancer	0.000227	0.00148	CcSEcCtD
Gliclazide—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000223	0.00145	CcSEcCtD
Gliclazide—Renal failure acute—Epirubicin—thyroid cancer	0.000223	0.00145	CcSEcCtD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.00022	0.00342	CbGpPWpGaD
Gliclazide—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00022	0.00143	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000219	0.00342	CbGpPWpGaD
Gliclazide—Increased appetite—Epirubicin—thyroid cancer	0.000219	0.00142	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000219	0.00142	CcSEcCtD
Gliclazide—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000217	0.00142	CcSEcCtD
Gliclazide—ABCC8—Metabolism—MINPP1—thyroid cancer	0.000217	0.00339	CbGpPWpGaD
Gliclazide—Urticaria—Sorafenib—thyroid cancer	0.000217	0.00141	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000217	0.00338	CbGpPWpGaD
Gliclazide—Photosensitivity—Doxorubicin—thyroid cancer	0.000216	0.00141	CcSEcCtD
Gliclazide—Body temperature increased—Sorafenib—thyroid cancer	0.000216	0.00141	CcSEcCtD
Gliclazide—Abdominal pain—Sorafenib—thyroid cancer	0.000216	0.00141	CcSEcCtD
Gliclazide—Renal impairment—Epirubicin—thyroid cancer	0.000216	0.00141	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—KRAS—thyroid cancer	0.000214	0.00334	CbGpPWpGaD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	0.000213	0.00332	CbGpPWpGaD
Gliclazide—Hepatic failure—Doxorubicin—thyroid cancer	0.000212	0.00138	CcSEcCtD
Gliclazide—Eczema—Doxorubicin—thyroid cancer	0.000212	0.00138	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—MINPP1—thyroid cancer	0.000211	0.00328	CbGpPWpGaD
Gliclazide—Hypoglycaemia—Epirubicin—thyroid cancer	0.00021	0.00137	CcSEcCtD
Gliclazide—Cardiac failure—Epirubicin—thyroid cancer	0.00021	0.00137	CcSEcCtD
Gliclazide—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00021	0.00136	CcSEcCtD
Gliclazide—Hyponatraemia—Epirubicin—thyroid cancer	0.000206	0.00134	CcSEcCtD
Gliclazide—Renal failure acute—Doxorubicin—thyroid cancer	0.000206	0.00134	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000205	0.00134	CcSEcCtD
Gliclazide—Osteoarthritis—Epirubicin—thyroid cancer	0.000205	0.00134	CcSEcCtD
Gliclazide—Pain in extremity—Epirubicin—thyroid cancer	0.000205	0.00134	CcSEcCtD
Gliclazide—Diplopia—Epirubicin—thyroid cancer	0.000205	0.00134	CcSEcCtD
Gliclazide—Increased appetite—Doxorubicin—thyroid cancer	0.000202	0.00132	CcSEcCtD
Gliclazide—Hypersensitivity—Sorafenib—thyroid cancer	0.000201	0.00131	CcSEcCtD
Gliclazide—Renal impairment—Doxorubicin—thyroid cancer	0.0002	0.0013	CcSEcCtD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000199	0.0031	CbGpPWpGaD
Gliclazide—Asthenia—Sorafenib—thyroid cancer	0.000196	0.00128	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—KRAS—thyroid cancer	0.000196	0.00305	CbGpPWpGaD
Gliclazide—Cardiac failure—Doxorubicin—thyroid cancer	0.000195	0.00127	CcSEcCtD
Gliclazide—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000195	0.00127	CcSEcCtD
Gliclazide—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000194	0.00126	CcSEcCtD
Gliclazide—Pruritus—Sorafenib—thyroid cancer	0.000193	0.00126	CcSEcCtD
Gliclazide—Hyponatraemia—Doxorubicin—thyroid cancer	0.000191	0.00124	CcSEcCtD
Gliclazide—Pain in extremity—Doxorubicin—thyroid cancer	0.00019	0.00124	CcSEcCtD
Gliclazide—Osteoarthritis—Doxorubicin—thyroid cancer	0.00019	0.00124	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.00019	0.00124	CcSEcCtD
Gliclazide—Diplopia—Doxorubicin—thyroid cancer	0.00019	0.00124	CcSEcCtD
Gliclazide—Dry skin—Epirubicin—thyroid cancer	0.000188	0.00123	CcSEcCtD
Gliclazide—Diarrhoea—Sorafenib—thyroid cancer	0.000187	0.00122	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000185	0.0012	CcSEcCtD
Gliclazide—ABCC8—Metabolism—NDUFA13—thyroid cancer	0.000185	0.00288	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BRAF—thyroid cancer	0.000184	0.00287	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—HRAS—thyroid cancer	0.000182	0.00284	CbGpPWpGaD
Gliclazide—Gastritis—Epirubicin—thyroid cancer	0.000182	0.00118	CcSEcCtD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000181	0.00282	CbGpPWpGaD
Gliclazide—Dizziness—Sorafenib—thyroid cancer	0.000181	0.00118	CcSEcCtD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00018	0.00281	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NDUFA13—thyroid cancer	0.000179	0.00279	CbGpPWpGaD
Gliclazide—Abdominal distension—Epirubicin—thyroid cancer	0.000179	0.00116	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—PRKAR1A—thyroid cancer	0.000178	0.00278	CbGpPWpGaD
Gliclazide—Asthma—Epirubicin—thyroid cancer	0.000178	0.00116	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—CDK1—thyroid cancer	0.000175	0.00273	CbGpPWpGaD
Gliclazide—Dry skin—Doxorubicin—thyroid cancer	0.000174	0.00113	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—thyroid cancer	0.000174	0.00271	CbGpPWpGaD
Gliclazide—Vomiting—Sorafenib—thyroid cancer	0.000174	0.00113	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CHST14—thyroid cancer	0.000174	0.00271	CbGpPWpGaD
Gliclazide—Angina pectoris—Epirubicin—thyroid cancer	0.000173	0.00113	CcSEcCtD
Gliclazide—Rash—Sorafenib—thyroid cancer	0.000172	0.00112	CcSEcCtD
Gliclazide—Dermatitis—Sorafenib—thyroid cancer	0.000172	0.00112	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000172	0.00268	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—CP—thyroid cancer	0.000172	0.00268	CbGpPWpGaD
Gliclazide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000171	0.00111	CcSEcCtD
Gliclazide—Headache—Sorafenib—thyroid cancer	0.000171	0.00111	CcSEcCtD
Gliclazide—Bronchitis—Epirubicin—thyroid cancer	0.000171	0.00111	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000169	0.00263	CbGpPWpGaD
Gliclazide—Pancytopenia—Epirubicin—thyroid cancer	0.000169	0.0011	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CHST14—thyroid cancer	0.000168	0.00262	CbGpPWpGaD
Gliclazide—Gastritis—Doxorubicin—thyroid cancer	0.000168	0.0011	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HRAS—thyroid cancer	0.000166	0.00259	CbGpPWpGaD
Gliclazide—Abdominal distension—Doxorubicin—thyroid cancer	0.000165	0.00108	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000165	0.00107	CcSEcCtD
Gliclazide—Asthma—Doxorubicin—thyroid cancer	0.000164	0.00107	CcSEcCtD
Gliclazide—Nausea—Sorafenib—thyroid cancer	0.000162	0.00106	CcSEcCtD
Gliclazide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000162	0.00106	CcSEcCtD
Gliclazide—Weight increased—Epirubicin—thyroid cancer	0.000162	0.00105	CcSEcCtD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000161	0.00251	CbGpPWpGaD
Gliclazide—Hyperglycaemia—Epirubicin—thyroid cancer	0.00016	0.00104	CcSEcCtD
Gliclazide—Angina pectoris—Doxorubicin—thyroid cancer	0.00016	0.00104	CcSEcCtD
Gliclazide—Pneumonia—Epirubicin—thyroid cancer	0.000159	0.00104	CcSEcCtD
Gliclazide—Drowsiness—Epirubicin—thyroid cancer	0.000158	0.00103	CcSEcCtD
Gliclazide—Bronchitis—Doxorubicin—thyroid cancer	0.000158	0.00103	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000157	0.00102	CcSEcCtD
Gliclazide—Pancytopenia—Doxorubicin—thyroid cancer	0.000156	0.00102	CcSEcCtD
Gliclazide—Renal failure—Epirubicin—thyroid cancer	0.000156	0.00101	CcSEcCtD
Gliclazide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000155	0.00101	CcSEcCtD
Gliclazide—Jaundice—Epirubicin—thyroid cancer	0.000154	0.001	CcSEcCtD
Gliclazide—Conjunctivitis—Epirubicin—thyroid cancer	0.000154	0.001	CcSEcCtD
Gliclazide—Urinary tract infection—Epirubicin—thyroid cancer	0.000154	0.001	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—BRAF—thyroid cancer	0.000153	0.00239	CbGpPWpGaD
Gliclazide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000153	0.000994	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—thyroid cancer	0.000153	0.00238	CbGpPWpGaD
Gliclazide—Sweating—Epirubicin—thyroid cancer	0.000152	0.000988	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—AKT1—thyroid cancer	0.000151	0.00235	CbGpPWpGaD
Gliclazide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00015	0.000976	CcSEcCtD
Gliclazide—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00015	0.000975	CcSEcCtD
Gliclazide—Weight increased—Doxorubicin—thyroid cancer	0.00015	0.000973	CcSEcCtD
Gliclazide—Epistaxis—Epirubicin—thyroid cancer	0.000149	0.000972	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—AKT1—thyroid cancer	0.000149	0.00232	CbGpPWpGaD
Gliclazide—Sinusitis—Epirubicin—thyroid cancer	0.000149	0.000967	CcSEcCtD
Gliclazide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000148	0.000965	CcSEcCtD
Gliclazide—Agranulocytosis—Epirubicin—thyroid cancer	0.000148	0.000962	CcSEcCtD
Gliclazide—Pneumonia—Doxorubicin—thyroid cancer	0.000147	0.000959	CcSEcCtD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000147	0.00229	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—AKT1—thyroid cancer	0.000147	0.00229	CbGpPWpGaD
Gliclazide—Drowsiness—Doxorubicin—thyroid cancer	0.000146	0.000954	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000145	0.000945	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000145	0.00226	CbGpPWpGaD
Gliclazide—Bradycardia—Epirubicin—thyroid cancer	0.000145	0.000942	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—NRAS—thyroid cancer	0.000144	0.00225	CbGpPWpGaD
Gliclazide—Renal failure—Doxorubicin—thyroid cancer	0.000144	0.000937	CcSEcCtD
Gliclazide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000144	0.000935	CcSEcCtD
Gliclazide—Jaundice—Doxorubicin—thyroid cancer	0.000143	0.00093	CcSEcCtD
Gliclazide—Rhinitis—Epirubicin—thyroid cancer	0.000142	0.000928	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—HIF1A—thyroid cancer	0.000142	0.00222	CbGpPWpGaD
Gliclazide—Urinary tract infection—Doxorubicin—thyroid cancer	0.000142	0.000927	CcSEcCtD
Gliclazide—Conjunctivitis—Doxorubicin—thyroid cancer	0.000142	0.000927	CcSEcCtD
Gliclazide—Hepatitis—Epirubicin—thyroid cancer	0.000142	0.000925	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—thyroid cancer	0.000142	0.00221	CbGpPWpGaD
Gliclazide—Hypoaesthesia—Epirubicin—thyroid cancer	0.000141	0.000921	CcSEcCtD
Gliclazide—Pharyngitis—Epirubicin—thyroid cancer	0.000141	0.000918	CcSEcCtD
Gliclazide—Sweating—Doxorubicin—thyroid cancer	0.00014	0.000914	CcSEcCtD
Gliclazide—ABCC8—Metabolism—HPGD—thyroid cancer	0.00014	0.00218	CbGpPWpGaD
Gliclazide—Oedema peripheral—Epirubicin—thyroid cancer	0.00014	0.000911	CcSEcCtD
Gliclazide—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000139	0.000902	CcSEcCtD
Gliclazide—Epistaxis—Doxorubicin—thyroid cancer	0.000138	0.000899	CcSEcCtD
Gliclazide—Sinusitis—Doxorubicin—thyroid cancer	0.000137	0.000895	CcSEcCtD
Gliclazide—Visual impairment—Epirubicin—thyroid cancer	0.000137	0.000892	CcSEcCtD
Gliclazide—Agranulocytosis—Doxorubicin—thyroid cancer	0.000137	0.00089	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—HPGD—thyroid cancer	0.000136	0.00212	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CCND1—thyroid cancer	0.000135	0.0021	CbGpPWpGaD
Gliclazide—Erythema multiforme—Epirubicin—thyroid cancer	0.000134	0.000875	CcSEcCtD
Gliclazide—Bradycardia—Doxorubicin—thyroid cancer	0.000134	0.000871	CcSEcCtD
Gliclazide—Eye disorder—Epirubicin—thyroid cancer	0.000133	0.000865	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CALCB—thyroid cancer	0.000133	0.00207	CbGpPWpGaD
Gliclazide—Tinnitus—Epirubicin—thyroid cancer	0.000133	0.000863	CcSEcCtD
Gliclazide—Flushing—Epirubicin—thyroid cancer	0.000132	0.000859	CcSEcCtD
Gliclazide—Rhinitis—Doxorubicin—thyroid cancer	0.000132	0.000858	CcSEcCtD
Gliclazide—Hepatitis—Doxorubicin—thyroid cancer	0.000131	0.000856	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—thyroid cancer	0.000131	0.00205	CbGpPWpGaD
Gliclazide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000131	0.000852	CcSEcCtD
Gliclazide—Pharyngitis—Doxorubicin—thyroid cancer	0.000131	0.00085	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—PTEN—thyroid cancer	0.00013	0.00202	CbGpPWpGaD
Gliclazide—Oedema peripheral—Doxorubicin—thyroid cancer	0.00013	0.000843	CcSEcCtD
Gliclazide—ABCC8—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000129	0.002	CbGpPWpGaD
Gliclazide—Chills—Epirubicin—thyroid cancer	0.000128	0.00083	CcSEcCtD
Gliclazide—Arrhythmia—Epirubicin—thyroid cancer	0.000127	0.000827	CcSEcCtD
Gliclazide—Visual impairment—Doxorubicin—thyroid cancer	0.000127	0.000825	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—TRIM33—thyroid cancer	0.000126	0.00196	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CDK1—thyroid cancer	0.000125	0.00195	CbGpPWpGaD
Gliclazide—Mental disorder—Epirubicin—thyroid cancer	0.000125	0.000811	CcSEcCtD
Gliclazide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000124	0.000809	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—KRAS—thyroid cancer	0.000124	0.00193	CbGpPWpGaD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—thyroid cancer	0.000124	0.00193	CbGpPWpGaD
Gliclazide—Malnutrition—Epirubicin—thyroid cancer	0.000124	0.000805	CcSEcCtD
Gliclazide—Erythema—Epirubicin—thyroid cancer	0.000124	0.000805	CcSEcCtD
Gliclazide—ABCC8—Neuronal System—BRAF—thyroid cancer	0.000124	0.00192	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000123	0.00192	CbGpPWpGaD
Gliclazide—Eye disorder—Doxorubicin—thyroid cancer	0.000123	0.0008	CcSEcCtD
Gliclazide—Tinnitus—Doxorubicin—thyroid cancer	0.000123	0.000798	CcSEcCtD
Gliclazide—Flushing—Doxorubicin—thyroid cancer	0.000122	0.000794	CcSEcCtD
Gliclazide—Flatulence—Epirubicin—thyroid cancer	0.000122	0.000794	CcSEcCtD
Gliclazide—Tension—Epirubicin—thyroid cancer	0.000121	0.00079	CcSEcCtD
Gliclazide—Nervousness—Epirubicin—thyroid cancer	0.00012	0.000782	CcSEcCtD
Gliclazide—KCNJ11—Neuronal System—BRAF—thyroid cancer	0.00012	0.00187	CbGpPWpGaD
Gliclazide—Back pain—Epirubicin—thyroid cancer	0.00012	0.000779	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—IFNA2—thyroid cancer	0.000118	0.00184	CbGpPWpGaD
Gliclazide—Chills—Doxorubicin—thyroid cancer	0.000118	0.000768	CcSEcCtD
Gliclazide—Arrhythmia—Doxorubicin—thyroid cancer	0.000117	0.000765	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—RXRA—thyroid cancer	0.000116	0.00181	CbGpPWpGaD
Gliclazide—Mental disorder—Doxorubicin—thyroid cancer	0.000115	0.00075	CcSEcCtD
Gliclazide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000115	0.000747	CcSEcCtD
Gliclazide—Erythema—Doxorubicin—thyroid cancer	0.000114	0.000745	CcSEcCtD
Gliclazide—Malnutrition—Doxorubicin—thyroid cancer	0.000114	0.000745	CcSEcCtD
Gliclazide—Anaemia—Epirubicin—thyroid cancer	0.000114	0.000744	CcSEcCtD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000114	0.00178	CbGpPWpGaD
Gliclazide—Agitation—Epirubicin—thyroid cancer	0.000114	0.00074	CcSEcCtD
Gliclazide—Flatulence—Doxorubicin—thyroid cancer	0.000113	0.000734	CcSEcCtD
Gliclazide—Tension—Doxorubicin—thyroid cancer	0.000112	0.000731	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—CCND1—thyroid cancer	0.000112	0.00174	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—thyroid cancer	0.000112	0.00174	CbGpPWpGaD
Gliclazide—Malaise—Epirubicin—thyroid cancer	0.000112	0.000726	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000112	0.00174	CbGpPWpGaD
Gliclazide—Nervousness—Doxorubicin—thyroid cancer	0.000111	0.000724	CcSEcCtD
Gliclazide—Leukopenia—Epirubicin—thyroid cancer	0.000111	0.000721	CcSEcCtD
Gliclazide—Back pain—Doxorubicin—thyroid cancer	0.000111	0.000721	CcSEcCtD
Gliclazide—Palpitations—Epirubicin—thyroid cancer	0.000109	0.000712	CcSEcCtD
Gliclazide—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000109	0.0017	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000109	0.0017	CbGpPWpGaD
Gliclazide—Loss of consciousness—Epirubicin—thyroid cancer	0.000109	0.000708	CcSEcCtD
Gliclazide—VEGFA—Focal Adhesion—PTEN—thyroid cancer	0.000108	0.00168	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000108	0.00168	CbGpPWpGaD
Gliclazide—Cough—Epirubicin—thyroid cancer	0.000108	0.000703	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000108	0.00168	CbGpPWpGaD
Gliclazide—Convulsion—Epirubicin—thyroid cancer	0.000107	0.000698	CcSEcCtD
Gliclazide—Hypertension—Epirubicin—thyroid cancer	0.000107	0.000695	CcSEcCtD
Gliclazide—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000106	0.000691	CcSEcCtD
Gliclazide—Anaemia—Doxorubicin—thyroid cancer	0.000106	0.000689	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—thyroid cancer	0.000105	0.00164	CbGpPWpGaD
Gliclazide—Arthralgia—Epirubicin—thyroid cancer	0.000105	0.000686	CcSEcCtD
Gliclazide—Chest pain—Epirubicin—thyroid cancer	0.000105	0.000686	CcSEcCtD
Gliclazide—Myalgia—Epirubicin—thyroid cancer	0.000105	0.000686	CcSEcCtD
Gliclazide—Agitation—Doxorubicin—thyroid cancer	0.000105	0.000685	CcSEcCtD
Gliclazide—Anxiety—Epirubicin—thyroid cancer	0.000105	0.000683	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000105	0.000681	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000104	0.00162	CbGpPWpGaD
Gliclazide—Discomfort—Epirubicin—thyroid cancer	0.000104	0.000677	CcSEcCtD
Gliclazide—Malaise—Doxorubicin—thyroid cancer	0.000103	0.000672	CcSEcCtD
Gliclazide—Dry mouth—Epirubicin—thyroid cancer	0.000103	0.000671	CcSEcCtD
Gliclazide—Leukopenia—Doxorubicin—thyroid cancer	0.000102	0.000667	CcSEcCtD
Gliclazide—Confusional state—Epirubicin—thyroid cancer	0.000102	0.000663	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000101	0.00158	CbGpPWpGaD
Gliclazide—Palpitations—Doxorubicin—thyroid cancer	0.000101	0.000659	CcSEcCtD
Gliclazide—Loss of consciousness—Doxorubicin—thyroid cancer	0.000101	0.000655	CcSEcCtD
Gliclazide—Infection—Epirubicin—thyroid cancer	0.0001	0.000653	CcSEcCtD
Gliclazide—Cough—Doxorubicin—thyroid cancer	9.99e-05	0.00065	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—KRAS—thyroid cancer	9.97e-05	0.00155	CbGpPWpGaD
Gliclazide—Convulsion—Doxorubicin—thyroid cancer	9.92e-05	0.000646	CcSEcCtD
Gliclazide—Nervous system disorder—Epirubicin—thyroid cancer	9.9e-05	0.000645	CcSEcCtD
Gliclazide—Thrombocytopenia—Epirubicin—thyroid cancer	9.89e-05	0.000644	CcSEcCtD
Gliclazide—Hypertension—Doxorubicin—thyroid cancer	9.88e-05	0.000643	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—AKT1—thyroid cancer	9.86e-05	0.00154	CbGpPWpGaD
Gliclazide—Tachycardia—Epirubicin—thyroid cancer	9.85e-05	0.000642	CcSEcCtD
Gliclazide—Skin disorder—Epirubicin—thyroid cancer	9.81e-05	0.000638	CcSEcCtD
Gliclazide—Hyperhidrosis—Epirubicin—thyroid cancer	9.76e-05	0.000635	CcSEcCtD
Gliclazide—Arthralgia—Doxorubicin—thyroid cancer	9.75e-05	0.000634	CcSEcCtD
Gliclazide—Chest pain—Doxorubicin—thyroid cancer	9.75e-05	0.000634	CcSEcCtD
Gliclazide—Myalgia—Doxorubicin—thyroid cancer	9.75e-05	0.000634	CcSEcCtD
Gliclazide—Anxiety—Doxorubicin—thyroid cancer	9.71e-05	0.000632	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	9.68e-05	0.00063	CcSEcCtD
Gliclazide—Discomfort—Doxorubicin—thyroid cancer	9.63e-05	0.000627	CcSEcCtD
Gliclazide—Dry mouth—Doxorubicin—thyroid cancer	9.53e-05	0.00062	CcSEcCtD
Gliclazide—Hypotension—Epirubicin—thyroid cancer	9.43e-05	0.000614	CcSEcCtD
Gliclazide—Confusional state—Doxorubicin—thyroid cancer	9.42e-05	0.000613	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—AKT1—thyroid cancer	9.31e-05	0.00145	CbGpPWpGaD
Gliclazide—Infection—Doxorubicin—thyroid cancer	9.28e-05	0.000604	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	9.2e-05	0.000599	CcSEcCtD
Gliclazide—Nervous system disorder—Doxorubicin—thyroid cancer	9.16e-05	0.000596	CcSEcCtD
Gliclazide—Thrombocytopenia—Doxorubicin—thyroid cancer	9.15e-05	0.000595	CcSEcCtD
Gliclazide—Insomnia—Epirubicin—thyroid cancer	9.13e-05	0.000595	CcSEcCtD
Gliclazide—Tachycardia—Doxorubicin—thyroid cancer	9.12e-05	0.000594	CcSEcCtD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.1e-05	0.00142	CbGpPWpGaD
Gliclazide—Skin disorder—Doxorubicin—thyroid cancer	9.07e-05	0.000591	CcSEcCtD
Gliclazide—Paraesthesia—Epirubicin—thyroid cancer	9.07e-05	0.00059	CcSEcCtD
Gliclazide—Hyperhidrosis—Doxorubicin—thyroid cancer	9.03e-05	0.000588	CcSEcCtD
Gliclazide—Dyspnoea—Epirubicin—thyroid cancer	9e-05	0.000586	CcSEcCtD
Gliclazide—Somnolence—Epirubicin—thyroid cancer	8.98e-05	0.000584	CcSEcCtD
Gliclazide—Dyspepsia—Epirubicin—thyroid cancer	8.89e-05	0.000579	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—thyroid cancer	8.86e-05	0.00138	CbGpPWpGaD
Gliclazide—Hypotension—Doxorubicin—thyroid cancer	8.73e-05	0.000568	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Epirubicin—thyroid cancer	8.72e-05	0.000567	CcSEcCtD
Gliclazide—Fatigue—Epirubicin—thyroid cancer	8.7e-05	0.000567	CcSEcCtD
Gliclazide—Pain—Epirubicin—thyroid cancer	8.63e-05	0.000562	CcSEcCtD
Gliclazide—Constipation—Epirubicin—thyroid cancer	8.63e-05	0.000562	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—RXRA—thyroid cancer	8.56e-05	0.00133	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	8.51e-05	0.000554	CcSEcCtD
Gliclazide—Insomnia—Doxorubicin—thyroid cancer	8.45e-05	0.00055	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—TCF7L1—thyroid cancer	8.39e-05	0.00131	CbGpPWpGaD
Gliclazide—Paraesthesia—Doxorubicin—thyroid cancer	8.39e-05	0.000546	CcSEcCtD
Gliclazide—Dyspnoea—Doxorubicin—thyroid cancer	8.33e-05	0.000542	CcSEcCtD
Gliclazide—Feeling abnormal—Epirubicin—thyroid cancer	8.32e-05	0.000542	CcSEcCtD
Gliclazide—Somnolence—Doxorubicin—thyroid cancer	8.31e-05	0.000541	CcSEcCtD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.3e-05	0.00129	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.26e-05	0.00129	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Epirubicin—thyroid cancer	8.26e-05	0.000538	CcSEcCtD
Gliclazide—Dyspepsia—Doxorubicin—thyroid cancer	8.22e-05	0.000535	CcSEcCtD
Gliclazide—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	8.16e-05	0.00127	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	8.1e-05	0.00126	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	8.07e-05	0.000525	CcSEcCtD
Gliclazide—Fatigue—Doxorubicin—thyroid cancer	8.05e-05	0.000524	CcSEcCtD
Gliclazide—ABCC8—Metabolism—TPR—thyroid cancer	8.04e-05	0.00125	CbGpPWpGaD
Gliclazide—Urticaria—Epirubicin—thyroid cancer	8.02e-05	0.000522	CcSEcCtD
Gliclazide—Pain—Doxorubicin—thyroid cancer	7.99e-05	0.00052	CcSEcCtD
Gliclazide—Constipation—Doxorubicin—thyroid cancer	7.99e-05	0.00052	CcSEcCtD
Gliclazide—Abdominal pain—Epirubicin—thyroid cancer	7.98e-05	0.00052	CcSEcCtD
Gliclazide—Body temperature increased—Epirubicin—thyroid cancer	7.98e-05	0.00052	CcSEcCtD
Gliclazide—ABCC8—Metabolism—PRKAR1A—thyroid cancer	7.91e-05	0.00123	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—RXRA—thyroid cancer	7.81e-05	0.00122	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TPR—thyroid cancer	7.8e-05	0.00121	CbGpPWpGaD
Gliclazide—Feeling abnormal—Doxorubicin—thyroid cancer	7.7e-05	0.000501	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—PRKAR1A—thyroid cancer	7.67e-05	0.0012	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Doxorubicin—thyroid cancer	7.64e-05	0.000497	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	7.49e-05	0.00117	CbGpPWpGaD
Gliclazide—Hypersensitivity—Epirubicin—thyroid cancer	7.44e-05	0.000484	CcSEcCtD
Gliclazide—Urticaria—Doxorubicin—thyroid cancer	7.42e-05	0.000483	CcSEcCtD
Gliclazide—Body temperature increased—Doxorubicin—thyroid cancer	7.39e-05	0.000481	CcSEcCtD
Gliclazide—Abdominal pain—Doxorubicin—thyroid cancer	7.39e-05	0.000481	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.35e-05	0.00114	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PPARG—thyroid cancer	7.34e-05	0.00114	CbGpPWpGaD
Gliclazide—Asthenia—Epirubicin—thyroid cancer	7.24e-05	0.000472	CcSEcCtD
Gliclazide—Pruritus—Epirubicin—thyroid cancer	7.14e-05	0.000465	CcSEcCtD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	7.08e-05	0.0011	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—thyroid cancer	7.05e-05	0.0011	CbGpPWpGaD
Gliclazide—ALB—Metabolism—MINPP1—thyroid cancer	7.01e-05	0.00109	CbGpPWpGaD
Gliclazide—Diarrhoea—Epirubicin—thyroid cancer	6.91e-05	0.00045	CcSEcCtD
Gliclazide—Hypersensitivity—Doxorubicin—thyroid cancer	6.88e-05	0.000448	CcSEcCtD
Gliclazide—Asthenia—Doxorubicin—thyroid cancer	6.7e-05	0.000436	CcSEcCtD
Gliclazide—Dizziness—Epirubicin—thyroid cancer	6.68e-05	0.000435	CcSEcCtD
Gliclazide—Pruritus—Doxorubicin—thyroid cancer	6.61e-05	0.00043	CcSEcCtD
Gliclazide—Vomiting—Epirubicin—thyroid cancer	6.42e-05	0.000418	CcSEcCtD
Gliclazide—Diarrhoea—Doxorubicin—thyroid cancer	6.39e-05	0.000416	CcSEcCtD
Gliclazide—Rash—Epirubicin—thyroid cancer	6.37e-05	0.000414	CcSEcCtD
Gliclazide—Dermatitis—Epirubicin—thyroid cancer	6.36e-05	0.000414	CcSEcCtD
Gliclazide—Headache—Epirubicin—thyroid cancer	6.33e-05	0.000412	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—NRAS—thyroid cancer	6.29e-05	0.00098	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PRKAR1A—thyroid cancer	6.29e-05	0.00098	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—MINPP1—thyroid cancer	6.29e-05	0.00098	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—AKT1—thyroid cancer	6.23e-05	0.000971	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.2e-05	0.000966	CbGpPWpGaD
Gliclazide—Dizziness—Doxorubicin—thyroid cancer	6.18e-05	0.000402	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—TSHR—thyroid cancer	6.14e-05	0.000957	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—thyroid cancer	6.07e-05	0.000945	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PRKAR1A—thyroid cancer	6.04e-05	0.000942	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—SLC5A5—thyroid cancer	6.02e-05	0.000938	CbGpPWpGaD
Gliclazide—Nausea—Epirubicin—thyroid cancer	6e-05	0.00039	CcSEcCtD
Gliclazide—ALB—Metabolism—NDUFA13—thyroid cancer	5.96e-05	0.000928	CbGpPWpGaD
Gliclazide—Vomiting—Doxorubicin—thyroid cancer	5.94e-05	0.000387	CcSEcCtD
Gliclazide—Rash—Doxorubicin—thyroid cancer	5.89e-05	0.000383	CcSEcCtD
Gliclazide—Dermatitis—Doxorubicin—thyroid cancer	5.88e-05	0.000383	CcSEcCtD
Gliclazide—Headache—Doxorubicin—thyroid cancer	5.85e-05	0.000381	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—SLC5A5—thyroid cancer	5.84e-05	0.00091	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MEN1—thyroid cancer	5.78e-05	0.0009	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—MINPP1—thyroid cancer	5.73e-05	0.000893	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—thyroid cancer	5.68e-05	0.000885	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—thyroid cancer	5.67e-05	0.000883	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CHST14—thyroid cancer	5.6e-05	0.000873	CbGpPWpGaD
Gliclazide—Nausea—Doxorubicin—thyroid cancer	5.55e-05	0.000361	CcSEcCtD
Gliclazide—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	5.54e-05	0.000863	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	5.54e-05	0.000863	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	5.52e-05	0.00086	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—thyroid cancer	5.51e-05	0.000858	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.45e-05	0.000849	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—KRAS—thyroid cancer	5.42e-05	0.000844	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NDUFA13—thyroid cancer	5.35e-05	0.000833	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTCH1—thyroid cancer	5.22e-05	0.000814	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—RXRA—thyroid cancer	5.06e-05	0.000788	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CHST14—thyroid cancer	5.03e-05	0.000783	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—RXRA—thyroid cancer	4.9e-05	0.000764	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.88e-05	0.00076	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SST—thyroid cancer	4.78e-05	0.000744	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—thyroid cancer	4.6e-05	0.000717	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CALCA—thyroid cancer	4.6e-05	0.000717	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CHST14—thyroid cancer	4.58e-05	0.000714	CbGpPWpGaD
Gliclazide—ALB—Metabolism—HPGD—thyroid cancer	4.51e-05	0.000703	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NRAS—thyroid cancer	4.49e-05	0.0007	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—NRAS—thyroid cancer	4.4e-05	0.000686	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IFNA2—thyroid cancer	4.17e-05	0.000649	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CDK1—thyroid cancer	4.16e-05	0.000649	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.14e-05	0.000646	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—HPGD—thyroid cancer	4.05e-05	0.000631	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—KRAS—thyroid cancer	3.86e-05	0.000602	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—KRAS—thyroid cancer	3.79e-05	0.000591	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—HPGD—thyroid cancer	3.7e-05	0.000576	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.66e-05	0.000571	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.48e-05	0.000543	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—thyroid cancer	3.37e-05	0.000525	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRG1—thyroid cancer	3.34e-05	0.000521	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.29e-05	0.000512	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—thyroid cancer	3.28e-05	0.000512	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—thyroid cancer	3.22e-05	0.000502	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—thyroid cancer	3.19e-05	0.000498	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—thyroid cancer	3.1e-05	0.000482	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TERT—thyroid cancer	3e-05	0.000467	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3e-05	0.000467	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—thyroid cancer	2.9e-05	0.000452	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HIF1A—thyroid cancer	2.87e-05	0.000447	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—thyroid cancer	2.85e-05	0.000443	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TPR—thyroid cancer	2.59e-05	0.000404	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PRKAR1A—thyroid cancer	2.55e-05	0.000397	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—thyroid cancer	2.51e-05	0.000391	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—thyroid cancer	2.44e-05	0.00038	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—BRAF—thyroid cancer	2.38e-05	0.00037	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TPR—thyroid cancer	2.33e-05	0.000363	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.31e-05	0.00036	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.29e-05	0.000357	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—thyroid cancer	2.19e-05	0.000341	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—thyroid cancer	2.12e-05	0.000331	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TPR—thyroid cancer	2.12e-05	0.000331	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.09e-05	0.000325	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.08e-05	0.000323	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.95e-05	0.000304	CbGpPWpGaD
Gliclazide—ALB—Metabolism—SLC5A5—thyroid cancer	1.94e-05	0.000302	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.89e-05	0.000295	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.82e-05	0.000283	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.74e-05	0.000271	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—thyroid cancer	1.73e-05	0.00027	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—thyroid cancer	1.67e-05	0.000261	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.63e-05	0.000254	CbGpPWpGaD
Gliclazide—ALB—Metabolism—RXRA—thyroid cancer	1.63e-05	0.000254	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.59e-05	0.000248	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.59e-05	0.000247	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NRAS—thyroid cancer	1.55e-05	0.000242	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NRAS—thyroid cancer	1.49e-05	0.000233	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.49e-05	0.000232	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—RXRA—thyroid cancer	1.46e-05	0.000228	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.42e-05	0.000222	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—KRAS—thyroid cancer	1.34e-05	0.000208	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—RXRA—thyroid cancer	1.33e-05	0.000208	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.3e-05	0.000202	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KRAS—thyroid cancer	1.29e-05	0.0002	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—thyroid cancer	1.26e-05	0.000197	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—thyroid cancer	1.22e-05	0.000191	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—thyroid cancer	1.19e-05	0.000185	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—thyroid cancer	1.14e-05	0.000178	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—thyroid cancer	1.14e-05	0.000177	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—thyroid cancer	1.09e-05	0.00017	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—thyroid cancer	1.03e-05	0.00016	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—thyroid cancer	1e-05	0.000156	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—thyroid cancer	9.65e-06	0.00015	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—thyroid cancer	9.24e-06	0.000144	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—thyroid cancer	8.43e-06	0.000131	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—thyroid cancer	8.1e-06	0.000126	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—thyroid cancer	7.27e-06	0.000113	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—thyroid cancer	7.06e-06	0.00011	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—thyroid cancer	6.63e-06	0.000103	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—thyroid cancer	6.34e-06	9.88e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—thyroid cancer	5.78e-06	9.01e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—thyroid cancer	4.07e-06	6.34e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—thyroid cancer	3.65e-06	5.69e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—thyroid cancer	3.33e-06	5.19e-05	CbGpPWpGaD
